|
| 37005005 | Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care. | | 2023 |
| 36315097 | Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants. | Journal of the National Cancer Institute | 2023 |
| 35396271 | Contribution of large genomic rearrangements in to familial breast cancer: implications for genetic testing. | Journal of Medical Genetics | 2023 |
| 37553371 | Impact of a risk based breast screening decision aid on understanding, acceptance and decision making. | | 2023 |
| 36969007 | Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases. | Front Oncol | 2023 |
| 36833203 | Molecular Genetic Characteristics of <i>FANCI</i>, a Proposed New Ovarian Cancer Predisposing Gene. | Genes (Basel) | 2023 |
| 36763037 | Population-based testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study. | | 2023 |
| 36948887 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2023 |
| 35060087 | Development and pilot testing of an online decision aid for women considering risk-stratified breast screening. | Journal of Community Genetics | 2022 |
| 35972781 | Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial. | Acta Oncol | 2022 |
| 35768582 | Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. | NPJ Precis Oncol | 2022 |
| 36222710 | Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. | Clin Cancer Res | 2022 |
| 36210504 | Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci. | J Natl Cancer Inst | 2022 |
| 34320204 | Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. | J Natl Cancer Inst | 2022 |
| 35039523 | Integration of tumour sequencing and case-control data to assess pathogenicity of RAD51C missense variants in familial breast cancer. | npj Breast Cancer | 2022 |
| 35191126 | Estimating the proportion of pathogenic variants from breast cancer case-control data: Application to calibration of ACMG/AMP variant classification criteria. | Hum Mutat | 2022 |
| 34897700 | Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. | J Pathol | 2022 |
| 34480602 | Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. | European Journal of Clinical Pharmacology | 2022 |
| 34861889 | A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. | Genome Med | 2021 |
| 34117267 | Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study. | npj Breast Cancer | 2021 |
| 33980861 | Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. | NPJ Breast Cancer | 2021 |
| 33755789 | Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study. | Cancer Chemotherapy and Pharmacology | 2021 |
| 32546565 | Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer. | J Med Genet | 2021 |
| 33151585 | Primary mucinous ovarian neoplasms rarely show germ cell histogenesis. | Histopathology | 2021 |
| 32901952 | Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. | J Pathol | 2021 |
| 33161572 | Ethical and practical implications of returning genetic research results: two Australian case studies. | Medical Journal of Australia | 2021 |
| 34918982 | Unselected Women's Experiences of Receiving Genetic Research Results for Hereditary Breast and Ovarian Cancer: A Qualitative Study. | Genetic Testing and Molecular Biomarkers | 2021 |
| 32698852 | Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours. | BMC Res Notes | 2020 |
| 32357859 | Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei. | BMC Cancer | 2020 |
| 32242007 | Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes. | Nature Communications | 2020 |
| 31723001 | Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. | Cancer Res | 2020 |
| 31239549 | A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. | Mod Pathol | 2019 |
| 30312457 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. | J Natl Cancer Inst | 2019 |
| 30166312 | Mutational Landscape of Ovarian Adult Granulosa Cell Tumors from Whole Exome and Targeted Promoter Sequencing. | Molecular Cancer Research | 2019 |
| 30254378 | Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. | Genetics in Medicine | 2019 |
| 30683880 | Shared heritability and functional enrichment across six solid cancers. | Nat Commun | 2019 |
| 31213659 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. | Br J Cancer | 2019 |
| 30949688 | Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer. | J Natl Cancer Inst | 2019 |
| 30843206 | Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. | J Pathol | 2019 |
| 31003994 | A Natural Progression: Australian Women's Attitudes About an Individualized Breast Screening Model. | Cancer Prevention Research | 2019 |
| 31001917 | Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. | Cancer Med | 2019 |
| 31548585 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers. | Nat Commun | 2019 |
| 29316957 | Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs. | Breast Cancer Research | 2018 |
| 29979793 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. | PLoS One | 2018 |
| 30054336 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. | Cancer Res | 2018 |
| 30572910 | Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women. | Breast Cancer Research | 2018 |
| 30134598 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. | Int J Mol Sci | 2018 |
| 30627526 | When Is "Type I" Ovarian Cancer Not "Type I"? Indications of an Out-Dated Dichotomy. | Frontiers in Oncology | 2018 |
| 30224651 | Mutations in RECQL are not associated with breast cancer risk in an Australian population. | Nature Genetics | 2018 |
| 29720211 | Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape. | Breast Cancer Research | 2018 |